Article
Medicine, General & Internal
Sijian Li, Xinyue Zhang, Tianyu Zhang, Min Yin, Dongyan Cao, Yang Xiang, Jiaxin Yang
Summary: The prognostic factors for POIT include positive postoperative tumor markers and FIGO stage II-IV. Active surveillance may be practical for patients with negative postoperative tumor markers in stage I POIT.
ANNALS OF MEDICINE
(2023)
Review
Obstetrics & Gynecology
Zuoxi He, Yukun Lu, Chuan Xie
Summary: This case report highlights the importance of a multidisciplinary team assessing the benefits and risks of timely treatment for patients with immature ovarian teratoma during pregnancy. Early diagnosis, timing of surgery and chemotherapy, and the choice of chemotherapy regimen such as BEP are crucial factors for determining the prognosis. Surgery and combination chemotherapy with BEP play a significant role in the successful treatment of immature teratomas in pregnancy, leading to satisfactory outcomes for both mother and fetus.
BMC PREGNANCY AND CHILDBIRTH
(2022)
Article
Oncology
Emily Butts, Denise Gococo-Benore, Tanmayi Pai, Muhamad Alhaj Moustafa, Fei Heng, Ruqin Chen, Yujie Zhao, Rami Manochakian, Yanyan Lou
Summary: The objective of this study is to assess the pattern of recurrence and development of second primary lung cancer in patients with stage I non-small cell lung cancer following curative therapy. It was found that negative tobacco history and stage IA tumors were associated with prolonged disease-free survival, while tobacco history and stage IB were risk factors for recurrence. An individualized approach based on risk factors should be taken into consideration when deciding to continue CT surveillance after five years post curative therapy for stage I NSCLC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Surgery
Zechuan Jin, Qingbin Wu, Xiangbing Deng, Ziqiang Wang
Summary: This study investigated the survival and recurrence of stage I colorectal cancer (CRC) patients. The analysis of preoperative serological values revealed that age, white blood cell count, and the systemic inflammation index (SII) were associated with overall survival (OS), while elevated carcinoembryonic antigen (CEA) levels were related to disease-free survival (DFS). These findings suggest that stage I CRC patients still carry a clinically significant risk of recurrence, and further validation is needed to identify high-risk patients with less severe disease.
ASIAN JOURNAL OF SURGERY
(2022)
Article
Obstetrics & Gynecology
Xinyue Zhang, Jie Yang, Jinhui Wang, Ying Zhang, Jiaxin Yang
Summary: This study compared the survival outcomes in patients with stage I ovarian ITs who underwent surveillance or adjuvant chemotherapy, and found no significant difference in survival rates between the two groups. The results suggest that surveillance may be a safe and preferable option for early-stage IT patients.
GYNECOLOGIC ONCOLOGY REPORTS
(2022)
Article
Medicine, General & Internal
Sixia Xie, Xibiao Jia, Tingting Li, Yuanyuan Xu, Weiwei Wu, Yichao Qiu, Shuang Yuan, Xue Peng, Hongjing Wang
Summary: This study reports the incidence of pelvic masses after surgery for immature ovarian teratoma and identifies prognostic factors for disease-free survival. It suggests that lymph node dissection and chemotherapy are recommended to reduce recurrence, and close surveillance and surgical intervention are important for the management of new pelvic masses.
Article
Oncology
Uros Bumbasirevic, Marko Zivkovic, Milos Petrovic, Vesna Coric, Nikola Lisicic, Nebojsa Bojanic
Summary: In the treatment of seminoma, routine radiotherapy is no longer recommended for clinical stage I patients. Instead, a risk-adapted approach is preferred, with adjuvant carboplatin chemotherapy as the main treatment option. Active surveillance can prevent overtreatment but requires strict follow-up and increased radiation exposure.
Article
Surgery
Yozo Kudose, Dai Shida, Yuka Ahiko, Yuya Nakamura, Ryohei Sakamoto, Konosuke Moritani, Shunsuke Tsukamoto, Yukihide Kanemitsu
Summary: This study aimed to investigate the transitions of recurrence hazard and peak recurrence time in patients with nonmetastatic CRC. The study found that the recurrence rates and hazard curves varied among different stages of CRC. It was suggested that short-interval surveillance might not be necessary for stage I patients for the first 3 years after surgery, whereas short-interval surveillance for the first 3 years should be considered for stage III patients.
Article
Oncology
Bela Mrinakova, Karol Kajo, Viera Lehotska, Martina Ondrusova, Sona Balogova, Zuzana Pinakova, Vera Novotna, Vanda Usakova, Lucia Fedorkova, Iveta Waczulikova, Juraj Kausitz, Dalibor Ondrus
Summary: This study compared the impact of active surveillance (S) and adjuvant chemotherapy (ACT) on the survival of patients with clinical stage I testicular seminoma. The results suggest that for high-risk patients, ACT may be a suitable treatment, while S is a viable option for low-risk patients.
Article
Oncology
Dan Wang, Wei Cang, Shan Zhu, Congwei Jia, Dongyan Cao, Jiaxin Yang, Yang Xiang
Summary: The study evaluated the oncological and reproductive outcomes in patients with advanced-stage ovarian immature teratoma (IMT). The results showed that IMT has a favorable prognosis. Fertility-sparing surgery (FSS) is feasible for patients who wish to preserve their fertility.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Shaobo Mo, Li Ye, Dongyang Wang, Lingyu Han, Shuang Zhou, Hui Wang, Weixing Dai, Yichao Wang, Wenqin Luo, Renjie Wang, Ye Xu, Sanjun Cai, Rui Liu, Zheng Wang, Guoxiang Cai
Summary: Measurement of circulating tumor DNA (ctDNA) with 6 DNA methylation markers in blood samples may enable early detection of recurrence and improve treatment of colorectal cancer (CRC) patients.
Review
Urology & Nephrology
Christian G. Ruf, Stefanie Schmidt, Sabine Kliesch, Christoph Oing, David Pfister, Jonas Busch, Julia Heinzelbecker, Christian Winter, Friedemann Zengerling, Peter Albers, Karin Oechsle, Susanne Krege, Julia Lackner, Klaus-Peter Dieckmann
Summary: This systematic review evaluates the treatment outcomes of active surveillance compared to adjuvant strategies in patients with clinical stage I (CSI) testicular germ cell tumors (GCTs). The results show that active surveillance offers similar overall survival to adjuvant management in both non-seminoma and pure seminoma patients, but with higher relapse rates.
WORLD JOURNAL OF UROLOGY
(2022)
Article
Reproductive Biology
Akari Nakamori, Hideaki Tsuyoshi, Tetsuya Tsujikawa, Makoto Orisaka, Tetsuji Kurokawa, Yoshio Yoshida
Summary: This study evaluated the differences in calcification and fat distributions between mature and immature teratomas using CT-based textural analysis. The results showed that calcification distribution can serve as a potential diagnostic biomarker to differentiate between the two types of tumors.
JOURNAL OF OVARIAN RESEARCH
(2023)
Article
Oncology
Helena Record, Elle Clelland, Harriet T. Rothschild, Mandeep Kaur, A. Jo Chien, Michelle Melisko, Hope S. Rugo, Firdows Mujir, Laura Huppert, Rita A. Mukhtar
Summary: This study investigated the use of endocrine therapy in premenopausal patients with invasive lobular carcinoma. The results showed that while most patients received standard adjuvant treatment, the use of ovarian function suppression and aromatase inhibitors increased significantly over time. The study also revealed an association between the use of aromatase inhibitors and improved disease-free survival, suggesting the need for further investigation into predictive factors for treatment selection.
Article
Public, Environmental & Occupational Health
Jesper Nors, Trine Block Mattesen, Deirdre Cronin -Fenton, Aurelie Mailhac, Jesper Bertram Bramsen, Kare Andersson Gotschalck, Rune Erichsen, Claus Lindbjerg Andersen
Summary: The purpose of this study is to revalidate a registry-based algorithm for identifying colorectal cancer recurrence in a contemporary cohort and to investigate the accuracy of estimating the time to recurrence. The algorithm detects recurrence based on diagnosis codes, receipt of chemotherapy, or pathological tissue assessment. In the validation cohort, the algorithm showed a sensitivity of 94% and a specificity of 98%. Restricting the algorithm to chemotherapy codes from oncology departments improved its positive predictive value. Overall, this algorithm is suitable for future observational studies.
CLINICAL EPIDEMIOLOGY
(2023)
Article
Oncology
D. Cibula, L. Dostalek, P. Hillemanns, G. Scambia, J. Jarkovsky, J. Persson, F. Raspagliesi, Z. Novak, A. Jaeger, M. E. Capilna, V. Weinberger, J. Klat, R. L. Schmidt, A. Lopez, G. Scibilia, R. Pareja, A. Kucukmetin, L. Kreitner, A. El-Balat, G. J. R. Pereira, S. Laufhutte, D. Isla-Ortiz, T. Toptas, B. Gil-Ibanez, I. Vergote, I. Runnenbaum
Summary: This study indicated that completing radical hysterectomy does not improve survival in cervical cancer patients with intraoperative lymph node involvement, regardless of tumor size or histological type. Abandoning uterine radical procedures and referring the patient for definitive chemoradiation may be a more appropriate choice.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
K. N. Moore, A. M. Oza, N. Colombo, A. Oaknin, G. Scambia, D. Lorusso, G. E. Konecny, S. Banerjee, C. G. Murphy, J. L. Tanyi, H. Hirte, J. A. Konner, P. C. Lim, M. Prasad-Hayes, B. J. Monk, P. Pautier, J. Wang, A. Berkenblit, I Vergote, M. J. Birrer
Summary: The study found that in patients with platinum-resistant EOC, MIRV did not significantly improve PFS compared to chemotherapy. However, MIRV showed superior outcomes in secondary endpoints, particularly in patients with high FR alpha expression, and had a more manageable safety profile compared to chemotherapy.
ANNALS OF ONCOLOGY
(2021)
Correction
Oncology
Antonino Ditto, Jvan Casarin, Ciro Pinelli, Anna M. Perrone, Paolo Scollo, Fabio Martinelli, Giorgio Bogani, Umberto Leone Roberti Maggiore, Mauro Signorelli, Valentina Chiappa, Giorgio Giorda, Giuseppe Scibilia, Pierandrea De Iaco, Mariateresa Evangelista, Fabio Ghezzi, Biagio Paolini, Salvatore Lo Vullo, Luigi Mariani, Rosanna Montone, Francesco Raspagliesi
EUROPEAN JOURNAL OF CANCER
(2021)
Correction
Oncology
Gabriella Ferrandina, Cynthia Aristei, Pietro R. Biondetti, Ferdinando Carlo Maria Cananzi, Paolo Casali, Francesca Ciccarone, Nicoletta Colombo, Alessandro Comandone, Renzo Corvo', Pierandrea De Iaco, Angelo Paolo Dei Tos, Vittorio Donato, Marco Fiore, Franchi, Angiolo Gadducci, Alessandro Gronchi, Stefano Guerriero, Amato Infante, Franco Odicino, Tommaso Pirronti, Vittorio Quagliuolo, Roberta Sanfilippo, Antonia Carla Testa, Gian Franco Zannoni, Giovanni Scambia, Domenica Lorusso
EUROPEAN JOURNAL OF CANCER
(2021)
Editorial Material
Oncology
D. Lorusso, G. Daniele
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Francesca Falcone, Enrico Breda, Gabriella Ferrandina, Mario Malzoni, Anna M. Perrone, Gennaro Cormio, Violante Di Donato, Luigi Frigerio, Giorgia Mangili, Francesco Raspagliesi, Anna Festi, Giuseppe Scibilia, Nicoletta Biglia, Roberto Sorio, Enrico Vizza, Nunzia S. Losito, Stefano Greggi
Summary: Despite the high rate of recurrence, fertility-sparing surgery provides good chances of reproductive success with no impact on disease-specific survival. The presence of invasive peritoneal implants affects disease-free survival but not disease-specific survival or reproductive outcome. The risk of recurrence does not seem to be related to ovarian preservation per se, but to the natural history of the initial peritoneal spread.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Grazia Artioli, Gaia Giannone, Giorgio Valabrega, Furio Maggiorotto, Sofia Genta, Sandro Pignata, Domenica Lorusso, Gennaro Cormio, Simona Scalone, Maria Ornella Nicoletto, Filippo Greco, Emanuela Rossi, Ilaria Spagnoletti, Ugo De Giorgi, Michele Orditura, Anna Maria Mosconi, Anila Kardhashi, Stefano Bogliolo, Lucia Borgato
Summary: By retrospectively analyzing clinical and pathological data of Italian BRCA mutated EOC patients, it was found that R = 0 was the only predictor of longer overall survival. Additionally, EOC patients with BRCA mutations who subsequently developed breast cancer are usually long-term survivors.
GYNECOLOGIC ONCOLOGY
(2021)
Review
Obstetrics & Gynecology
Serena Girardelli, Luigi Albano, Giorgia Mangili, Luca Valsecchi, Emanuela Rabaiotti, Paolo Ivo Cavoretto, Pietro Mortini, Massimo Candiani
Summary: The relationship between female hormones and meningiomas should be considered in the treatment of such diseases. Current research lacks unified guidelines, with management methods mostly based on personal strategies. Understanding the biological links between female hormones and meningiomas is crucial for correctly counseling patients.
REPRODUCTIVE SCIENCES
(2022)
Article
Oncology
Raimondo Di Liello, Laura Arenare, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria, Annamaria Ferrero, Saverio Cinieri, Andrea De Censi, Enrico Breda, Paolo Scollo, Ugo De Giorgi, Andrea Alberto Lissoni, Dionyssios Katsaros, Domenica Lorusso, Vanda Salutari, Sabrina Chiara Cecere, Mariateresa Lapresa, Margherita Nardin, Giorgio Bogani, Mariagrazia Distefano, Stefano Greggi, Piera Gargiulo, Clorinda Schettino, Ciro Gallo, Gennaro Daniele, Daniela Califano, Francesco Perrone, Sandro Pignata, Maria Carmela Piccirillo
Summary: In advanced cancer patients receiving chemotherapy, routine antithrombotic prophylaxis is not recommended. The incidence of thromboembolic events during treatment with bevacizumab plus chemotherapy was 6.0%, and it was not associated with patient characteristics or the use of antithrombotic prophylaxis, with no significant impact on long-term prognosis.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)
Article
Oncology
Concetta Laliscia, Angiolo Gadducci, Roberto Mattioni, Francesca Orlandi, Sabina Giusti, Amelia Barcellini, Michela Gabelloni, Riccardo Morganti, Emanuele Neri, Fabiola Paiar
Summary: This study assessed prognostic factors in locally advanced cervical cancer patients treated with cisplatin-based chemoradiotherapy using MRI data. Factors such as age, FIGO stage, and certain radiomic features were found to be significant in predicting patient outcomes. The combination of clinical and radiomics features can help in making more accurate treatment decisions for LACC patients.
Review
Oncology
Brigida Anna Maiorano, Mauro Francesco Pio Maiorano, Domenica Lorusso, Evaristo Maiello
Summary: Ovarian cancer (OC) is a leading cause of cancer-related deaths in women, with high recurrence rates in the advanced disease setting. Clinical trials of immune checkpoint inhibitors (ICIs) in OC have shown poor outcomes in terms of patient response and survival, leading to early termination of some studies. Combining ICIs with other drugs targeting different pathways may enhance efficacy, and the search for predictive biomarkers for ICIs response is crucial for patient selection.
Article
Oncology
Raffaella Cioffi, Maria Luisa Fais, Alice Bergamini, Valeria Stella Vanni, Luca Pagliardini, Enrico Papaleo, Giorgia Mangili, Massimo Candiani
Summary: This study established a predictive model for determining the risk of premature ovarian failure after chemotherapy in young post-pubertal women with cancer. By analyzing data from 348 oncological patients, the model includes factors such as age, number of chemotherapy lines, and specific chemotherapy schedules to aid in counseling on fertility and decision making for fertility preservation strategies.
Article
Medicine, General & Internal
Marina Fabbi, Delfina Costa, Daniela Russo, Laura Arenare, Gabriele Gaggero, Simona Signoriello, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Nunzia Simona Losito, Gilberto Filaci, Anna Spina, Daniela Califano, Giosue Scognamiglio, Angiolo Gadducci, Delia Mezzanzanica, Marina Bagnoli, Silvano Ferrini, Vincenzo Canzonieri, Paolo Chiodini, Francesco Perrone, Sandro Pignata
Summary: By investigating the expression of ADAM17 in ovarian cancer tissues, this study aimed to identify prognostic factors for advanced ovarian cancer patients undergoing first-line therapy. The results showed that high expression of ADAM17 was associated with worse prognosis, especially in patients with no residual disease at baseline.
Review
Oncology
Angiolo Gadducci, Giovanni D. Aletti, Fabio Landoni, Roberta Lazzari, Giorgia Mangili, Paola Olivas, Sandro Pignata, Vanda Salutari, Enrico Sartori, Giovanni Scambia, Gian Franco Zannoni, Roberto Sabbatini, Domenica Lorusso
Summary: This article summarizes evidence-based guidelines developed by the Italian Medical Oncology Association for the management of ovarian cancer patients. The guidelines cover surgical, chemotherapy, and molecularly targeted agents for early, advanced, and recurrent disease. Levels of evidence and strength of recommendation are reported for each issue.
Article
Oncology
Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frederic Selle, Simona Frezzini, Ugo De Giorgi, Patricia Pautier, Alessandra Bologna, Michele Orditura, Coraline Dubot, Angiolo Gadducci, Serafina Mammoliti, Isabelle Ray-Coquard, Elena Zafarana, Enrico Breda, Laure Favier, Antonio Ardizzoia, Saverio Cinieri, Remy Largillier, Daniela Sambataro, Emmanuel Guardiola, Rossella Lauria, Carmela Pisano, Francesco Raspagliesi, Giovanni Scambia, Gennaro Daniele, Francesco Perrone
Summary: This study focused on the efficacy of continuing bevacizumab combined with chemotherapy in ovarian cancer patients after first-line treatment. The results showed a significant prolongation of progression-free survival in the bevacizumab group, with more adverse events observed in the bevacizumab combination therapy group, although the mortality rate was slightly higher than that in the standard chemotherapy group.
